Few cohort epidemiologic myasthenia gravis (MG) studies have been published, 1,2 most of them with data from multiple databases and varying inclusion criteria. A review from 1996 reported an increasing MG incidence and prevalence. 3 Studies from the last 10 years refer to a yearly incidence between 4 and 11 per million 1, 2, 4 and a prevalence ranging from 70 to 150 per million. 1, 2, 4, 5 There is only one laboratory in Norway offering acetylcholine receptor (AChR) antibody testing and all samples are sent to this laboratory. Presence of AChR antibodies is nearly 100% specific for MG in individuals with symptoms. 6 The aims of this study were to determine the incidence and prevalence of AChR antibody-positive (seropositive) MG, to describe its gender-specific characteristics, and to examine epidemiologic trends during the last decades.
Methods. Norway had a population of 4,737,171 inhabitants on January 1, 2008, our chosen MG prevalence day (Statistics Norway-SSB, www.ssb. no). Since the start of our AChR antibody testing in 1983, patient's name, birth date, date of sample acquisition, and name of referring doctor have been documented. The study was approved by the ethical regional committee. The study population from 1983 to 2008 comprised 11,926 assays, and this population has been used to calculate the prevalence. From June 1994, data acquisition has been standardized and processed through a computerized record system. The study population from 1995 to 2008 comprised 8,742 assays, and has been used to calculate the incidence. The Norwegian National Registry was consulted to determine whether the patients were alive at the prevalence day.
All patients with AChR antibody concentrations above 0.4 nmol/L were defined as seropositive. 6 Statistical analysis. Incidence was defined as the annual number of new cases of seropositive MG. Prevalence was defined as the number of alive patients with seropositive MG. Incidence and prevalence were calculated per 1 million inhabitants per January 1 each year 1995-2008. Ninety-five percent confidence intervals were calculated using the Poisson distribution. Statistical software SPSS (15.0) and StatXact 7 were used for statistical analysis.
Results. There was a steady increase in the number of assays, from 47 in 1983 to 1,007 in 2007. The number of individual patients tested was 8,628: 5,521 women and 3,100 men (female:male ratio 1.8; 7 unknown).
There were 898 seropositive MG patients identified: 543 women and 350 men (female:male ratio 1.6; 5 unknown). Of these patients, 308 (34.2%) had their first-time positive AChR antibody test before age 50 years and 525 (58.4%) at age 50 years or later (figure). For 65 (7.2%) patients, this age was unknown.
Since 1995, 420 new seropositive MG patients were found. The total crude yearly incidence for 1995-2007 was 7.2 per million (95% confidence interval 6.5-7.9).
The prevalence of seropositive MG was 115.5 per million (95% confidence interval 106.1-125.7). On January 1, 2008, 547 of the 898 seropositive MG patients were still alive, 274 were dead, and the status of 77 patients was unknown. If we presume that survival ratio among these 77 patients is the same as in the rest of our seropositive MG population (66.6%), the prevalence of seropositive MG would be 126.2 per million.
Discussion. Seropositive MG had a yearly incidence from 1995 to 2008 of 7.2 per million.
The estimated prevalence of seropositive MG was 126.2 per million. Including a 15% stipulated portion of seronegative MG patients, 6 the prevalence of seropositive and seronegative MG combined can be estimated to 145 per million. The majority of the first-time AChR antibody-positive patients were older than age 50. Assuming that the first AChR antibody test was performed around MG onset, this finding implicates that MG should not be regarded as a younger women's disease.
The annual increase in tests analyzed during our study period combined with the constant number of new positives illustrates how the threshold for testing has been reduced over time.
The wide range of results reported on MG frequencies in previous studies indicates problems with case finding, different inclusion criteria, or difficulties in extrapolating incidence and prevalence to a nationwide level from small populations and multiple databases. 4, 5, 7 Our study has 4 major advantages: it is a nationwide study based on a population of 4.7 million, all information was collected from one source, it comprised an extended time period , and it was based on seropositive MG only, which can be determined by a specific test. Excluding seronegative MG minimizes the risk of diagnostic uncertainty, rendering the study population well defined and the results reliable.
LONG-TERM SUPERIORITY OF SUBTHALAMIC NUCLEUS STIMULATION OVER PALLIDOTOMY IN PARKINSON DISEASE
The results of our multicenter randomized controlled trial comparing unilateral pallidotomy with bilateral subthalamic nucleus (STN) stimulation in advanced Parkinson disease (PD) demonstrated that STN stimulation is more effective than pallidotomy up to 1 year postoperatively. 1, 2 Here we present the 4-year follow-up of this trial.
Methods.
Thirty-four patients with advanced PD were randomly assigned to have unilateral pallidotomy or bilateral STN stimulation. Inclusion and exclusion criteria and study methods were described previously. 1, 2 The 2 assessors were blinded to the treatment allocation during the complete follow-up. For patients allocated to unilateral pallidotomy, the protocol allowed STN stimulation at least 6 months after pallidotomy. Outcome measures were the off and on phase motor Unified Parkinson's Disease Rating Scale (UPDRS) scores, 3 dyskinesia severity (Clinical Dyskinesias Rating Scale), 4 functional status (activities of daily living [ADL] UPDRS), 3 PD Quality of Life questionnaire, 5 levodopa equivalent dose, 2 and adverse events. Difference in median change scores (4 years follow-up minus baseline) between treatment groups were analyzed using the Mann-Whitney U test or Kruskal-Wallis rank test, when appropriate. The primary analysis was done according to the intention-to-treat principle. If patients died during the follow-up, their last observation was carried forward. Additionally, an explorative ontreatment analysis was performed, analyzing the data by the treatment actually received (STN, pallidotomy, pallidotomy and STN).
Results.
Four of the 14 patients in the pallidotomy group died: 1 committed suicide 3 weeks after operation, 1 developed dementia and died of pneumonia 2 years after surgery, 1 died of cardiac valve disease After 4 years of follow-up, the median off phase motor UPDRS score improved from 46.5 to 34 points (27%; table) in the pallidotomy group and from 51.5 to 28 (46%) in the STN group. The difference in median motor UPDRS change scores between the 2 groups was 18.5 points ( p ϭ 0.04) in favor of the STN group.
In the group of pallidotomy patients, the median on phase motor UPDRS score worsened from 15.5 to 26 points (40%) between baseline and 4 years follow-up, whereas it was about stable at 21 points in the STN group. The difference in median change scores between the groups was 6.5 points ( p ϭ 0.04) in favor of the STN group.
On-treatment analyses (with and without death) also demonstrated differences among the 3 treatment groups in advantage of the STN-only group: p ϭ 0.03 and 0.04.
Ten patients in the pallidotomy group had adverse events, which were persistent in 9. Severe adverse events were suicide in 1 patient and development of dementia in another patient. The most frequent adverse event was drooling (6 patients; persistent in 3). All three patients with bilateral STN stimulation after pallidotomy had adverse events (mild depressive symptoms, dementia, and sexual disinhibition and excessive eating of sweets). In the STN group, 13 patients had adverse events, which were persistent in 11 patients. Cognitive and behavioral problems directly after surgery in 1 patient and gradual development of dementia in 2 patients were the most severe adverse events. The most common adverse event was emotional lability: 6 patients, persistent in 3.
Discussion.
The results of this randomized trial in patients with advanced PD demonstrate that the beneficial effects on motor symptoms of bilateral STN stimulation compared to unilateral pallidotomy are sustained up to 4 years after surgery. Despite the fact that 3 patients-originally allocated to pallidotomy-had stimulation during follow-up, the STN stimulation group still performs better 4 years after surgery. We could not demonstrate significant differences between the 2 types of surgeries with regard to the level of ADL functioning, quality of life, and levodopa equivalent dose, which might be explained by the small sample size studied.
Concerns about STN stimulation and adverse events are increasing, especially for the cognitive, mood, and behavioral features. 6 However, in a recent trial comparing STN stimulation with medication, neuropsychiatric problems were also relatively common in the medication group. 7 In our study, the fre- quency of adverse events was approximately the same for both treatments.
